|Private Placement / Financing Transactions
Elucida Oncology: The company raised $45.2 million of venture funding from undisclosed investors on June 15, 2023. Elucida Oncology is a developer of therapeutics designed to target cancer with precision engineering technology.
Theradaptive: The company raised $26 million of Series A venture funding from undisclosed investors on June 15, 2023. Theradaptive is a developer of a drug delivery and research platform
Feldan Therapeutics: The company raised $16.5 million of Series B venture funding from GC Biopharma, Amgen Ventures, and GC Cell on June 13, 2023. Investissement Québec and other undisclosed investors also participated in the round. Feldan Theraputics operates a biopharmaceutical company intended to specialize in the development of treatments based on the intracellular delivery of therapeutics.
RevMedica: The company raised $14 million of venture funding from undisclosed investors on June 14, 2023. The company manufactures surgical devices intended to enhance surgeon performance. The company’s first product in development is a laparoscopic surgical stapler.
Adaptive Phage Therapeutics: The company raised $12 million of Series B venture funding from Deerfield Management, AMR Action Fund, and other undisclosed investors on June 13, 2023, setting the company’s pre-money valuation at $23 million. Adaptive Phage Therapeutics operates a clinical-stage company intended to treat multi-drug resistant pathogenic bacteria.
Neuvivo: The company raised $11 million of venture funding in a deal led by PrimeStreet Consulting on June 15, 2023. Neuvivo develops novel therapeutics designed for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases.
Repair Biotechnologies: The company raised $8.4 million of venture funding from undisclosed investors on June 15, 2023. Repair Biotechnologies is an operator of a biotechnology company intended to focus on the reversal of age-associated thymic atrophy and consequent loss of immune function.
Dynamic42: The company raised an undisclosed amount of Series A venture funding from bm-t Beteiligungs management Thuringen on June 13, 2023. Dynamic42 develops human organ-on-chip technology designed to obtain scientific data related to human physiology.
Iome Bio: The company is in the process of raising Series A venture funding on June 15, 2023. Iome Bio is a developer of microbiome-based mechanisms intended to develop drugs for immuno-oncology.
Stemina Biomarker Discovery: The company raised an undisclosed amount of venture funding from Arenberg Holdings in June, 2023. Stemina Biomarker Discovery is a developer of molecular biomarkers designed to perform diagnosis and treat neurological disorders, including autism spectrum disorders.